Cowen & Co. Thinks Syros Pharmaceuticals’ Stock is Going to Recover

By Carrie Williams

In a report released today, Phil Nadeau from Cowen & Co. assigned a Buy rating to Syros Pharmaceuticals (NASDAQ: SYRS). The company’s shares opened today at $8.45, close to its 52-week low of $6.30.

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 9.8% and a 51.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Achillion Pharmaceuticals, and Catabasis Pharmaceuticals.

Currently, the analyst consensus on Syros Pharmaceuticals is Strong Buy and the average price target is $24.67, representing a 192.0% upside.

In a report issued on December 7, Oppenheimer also assigned a Buy rating to the stock with a $28 price target.

The company has a one-year high of $24.38 and a one-year low of $6.30. Currently, Syros Pharmaceuticals has an average volume of 282.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.